

# Alarming symptoms leading to severe COVID-19 pneumonia: a meta-analysis and validation

weiping ji<sup>1</sup>, Jing Zhang<sup>1</sup>, Bishnu Gautam<sup>1</sup>, Xudong Du<sup>1</sup>, Xinxin Chen<sup>1</sup>, Hui Xu<sup>1</sup>, Xiaoling Guo<sup>1</sup>, Zhenzhai Cai<sup>1</sup>, Jun Zhang<sup>2</sup>, and Xian Shen<sup>1</sup>

<sup>1</sup>Wenzhou Medical University Second Affiliated Hospital

<sup>2</sup>University of Kansas Medical Center

September 11, 2020

## Abstract

**Background:** To identify alarming symptoms that could potentially lead to severe form of COVID-19 pneumonia (i.e. novel coronavirus pneumonia: NCP), a disease that is now having pandemic spread. **Methods:** Articles from PubMed, Embase, Cochrane database and Google up to 24 February 2020 were systematically reviewed. 18 publications that had documented cases of COVID-19 pneumonia were identified. The relevant data were extracted, systematically reviewed and further evaluated using meta-analysis. We define severe COVID-19 pneumonia as the disease status that requires admission to the intensive care unit (ICU) and respiratory/circulatory support, which is in align with the guideline from the World Health Organization (WHO). **Results:** 14 studies including 1,424 patients were considered eligible and analyzed. Symptoms such as fever (89.2%), cough (67.2%), fatigue (43.6%) were quite common; but dizziness, hemoptysis, abdominal pain and conjunctival congestion/conjunctivitis were relatively rare. The incidence of dyspnea was significantly higher in patients with severe than non-severe COVID-19 pneumonia (42.7% vs.16.3%,  $p < 0.0001$ ). Similarly, fever and diarrhea were also drastically more common in patients with severe form ( $p = 0.0374$  and  $0.0267$ ). Further meta-analysis using three high-quality China-based studies confirmed such findings and showed that dyspnea, fever and diarrhea were 3.53 (OR: 3.53, 95%CI: 1.95-6.38), 1.70 (OR: 1.70, 95%CI: 1.01-2.87), and 1.80 (OR: 1.80, 95%CI: 1.06-3.03) folds higher respectively in patients with severe COVID-19 pneumonia. **Conclusion:** Dyspnea, fever and diarrhea are significantly more prevalent in patients with severe COVID-19 pneumonia, suggesting they are alarming symptoms that warrant close attention and timely management.

## What's already known about this topic?

- The outbreak of COVID-19 caused by the virus SARS-CoV-2 is now an ongoing pandemic.
- The clinical presentation of COVID-19 pneumonia can be very diversified, and in severe cases it could present as acute respiratory distress syndrome.

## What does this article add?

- This study is the systematic review and meta-analysis that was compared clinical symptoms in patients with severe and non-severe COVID-19 based in China.
- Fever and cough were the most common symptoms in patients with COVID-19 pneumonia.
- Dyspnea, fever are significantly more prevalent in patients with severe COVID-19 pneumonia.

## Background

In December 2019, a series of mystical pneumonia cases appeared and soon followed by an outbreak in Wuhan China, with clinical manifestations similar to those of viral pneumonia <sup>1</sup>. It was soon discovered that this virus outbreak was due to a novel coronavirus which is now named as severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) <sup>2</sup>. At present, this novel coronavirus caused disease (COVID-19) has

spread throughout China and is rapidly sweeping through countries all over the world<sup>3-5</sup>. Human-to-human transmission of this virus is clearly proven<sup>6,7</sup>. The clinical presentation of COVID-19 pneumonia can be very diversified, and in severe cases it could present as acute respiratory distress syndrome (ARDS) that is often followed by death<sup>8-11</sup>.

## Methods

### Sources and search criteria

We conducted a comprehensive systematic search in PubMed, Embase, Cochrane database and Google to identify all published studies that describe the clinical characteristics of COVID-19 pneumonia, using the search terms “novel coronavirus”, “SARS-CoV-2”, “COVID-19” and “novel coronavirus pneumonia”. Two independent researchers then reviewed all the results, selected and classified the studies.

### Inclusion and exclusion criteria

Publications must have described clinical signs and symptoms of COVID-19 pneumonia. If there were duplicates of study population, the publication with the largest sample size was used. Studies that did not describe the clinical features of COVID-19 pneumonia, as well as those were duplicated, were excluded. Articles published by the same author were carefully screened to rule out duplication.

### Data extraction and analysis

All studies that met the above-mentioned criteria were carefully analyzed and strictly reviewed. We collected relevant clinical information including the population data (e.g. age, gender), number of patients in the studies, and documented clinical manifestations. Full-text versions of relevant articles were reviewed, and clinical characteristics were extracted. The Newcastle-Ottawa quality assessment scale (NOS) was used to evaluate the quality of included studies<sup>12</sup>. A scale ranges from 0 to 9, with higher points indicating higher quality was applied. The two authors (WJ and XG) used a unified data table to extract data independently, and resolved controversial issues through further discussion. We define severe COVID-19 pneumonia as the disease status that requires intensive care unit (ICU) admission with respiratory/circulatory support<sup>10,11,13,14</sup>, which is in align with the guideline from the World Health Organization (WHO). We compared the clinical characteristics of severe and non-severe COVID-19 pneumonia, followed by a meta-analysis using three high quality China-based studies.

### Validation data extraction and analysis

To verify the results of the meta-analysis, all laboratory-confirmed COVID-19 cases in two hospitals in Wenzhou (the First and Second affiliated Hospitals of Wenzhou Medical University) from January 22 to February 22, 2020 were included. Follow-up was performed until discharge, death, or March 16, 2020. The basic characteristics of the patients were extracted and compared between severe and non-severe cases.

We extracted the following information: (1) Demographic characteristics, including age, gender, height and weight. According to Chinese adult obesity standards, patients were classified as obese (BMI[?]28.0), overweight (24.0[?]BMI<28.0), normal (18.5[?]BMI<24.0), and lean (BMI<18.5)<sup>15</sup>. (2) Wuhan exposure history: the patients were divided into four groups: direct exposure to Wuhan (the patient recently lived or visited Wuhan); indirect contact with Wuhan (close contact with people who had been to Wuhan during the epidemic); contact with other confirmed diagnoses patients; no clear history of contact. (3) Clinical symptoms, onset to hospitalization time.

### Statistical analysis

SAS 9.4 and Review Manager 5.3 software were used for analysis and data presentation. Continuous variables were represented by median and interquartile range (IQR). Classification variables were summarized as counts and percentages in each category. The age, gender, number and clinical signs of COVID-19 pneumonia patients were statistically described. Cochran-mantel-Haenszel test (stratified chi-square test) was used to compare the differences between severe and non-severe forms of COVID-19 pneumonia. With odds ratio

(OR) as the effect size we used Mantel-Haenszel test with fixed or random effect for further meta-analysis of the clinical signs, and presented using the forest map. The study precision/bias was measured using the funnel plot.

## Results

### Search result

A total of 333 relevant publications on PubMed and other databases were identified. 68 were removed because of duplication, and 224 were removed based on above-mentioned inclusion/exclusion criteria. 23 publications did not report clinical signs, and four were excluded due to overlapped cases<sup>8,9,16,17</sup>. Finally, 14 articles were included for analysis<sup>10,11,13,18-28</sup>. **Fig. 1** is the study selection flowchart. Data from all eligible studies were obtained from published manuscripts.

### Synthesis of results

A systematic review showed that 610 patients (42.8%) with COVID-19 pneumonia were female. Fever (89.2%) and cough (67.2%) were the most common symptoms, followed by fatigue (43.6%), phlegm (28.6%), and shortness/difficulty of breathing (21.7%). The less common symptoms were dizziness (0.9%), hemoptysis (0.8%), abdominal pain (0.8%), and conjunctiva congestion/conjunctivitis (0.7%). 1,377 cases were divided into groups of severe (1,110) and non-severe COVID-19 pneumonia (267). Stratified chi-square test showed that there was no significant difference in gender between the two groups ( $p > 0.05$ ), and the median age of severe patients was slightly older (details in Table 2). Dyspnea in patients of severe group was significantly more common than that in non-severe group (42.7% vs.16.3%,  $p < 0.0001$ ). The incidence of fever and diarrhea were also significantly higher in severe group ( $p = 0.0374$  and  $0.0267$  respectively). Although conjunctival congestion/conjunctivitis ( $p = 0.0176$ ), hemoptysis ( $p = 0.0344$ ), anorexia ( $p = 0.0008$ ), dizziness ( $p = 0.0023$ ) and abdominal pain ( $p = 0.0015$ ) all appeared to be much more common in severe patients, as the dates of these symptoms were only reported in one or two literatures, the inter-group comparisons of these symptoms should be treated with caution. (See **Table 1 and 2** )

### Meta-analysis results

Three high-quality studies, all of which were from China and clearly classified COVID-19 pneumonia as severe and non-severe were used for subsequent meta-analysis. When used to study fever, these studies included in total 262 cases in the severe group (245 cases with fever, 93.51%) and 1,095 cases in the non-severe group (967 cases with fever, 88.31%), and were considered to be homogeneous as they fit the fixed effect model nicely ( $\text{Chi}^2 = 0.88$ ,  $P = 0.64$ ,  $I^2 = 0\%$ ). The pooled effect was 1.70 (95%CI, 1.01- 2.87; **Fig. 2A** ), indicating that the incidence of fever in the severe group was 1.70 times higher than that of non-severe group. On symptoms of dyspnea, there were 262 cases in the severe group (112 dyspnea, 42.75%) and 1095 cases in the non-severe group (179 dyspnea, 68.32%). Q-test and  $I^2$  statistic test showed that certain heterogeneity exists ( $\text{Chi}^2 = 5.26$ ,  $P = 0.07$ ,  $I^2 = 62\%$ ), therefore the random effect model was adopted. The individual OR effect showed inconsistently that *Article 1* and *Article 2* show the severe patients have a higher incidence of dyspnea and *Article 3* shows there is no statistically significant difference, but combined OR effect was 3.53 (95%CI, 1.95-6.38; **Fig. 2B** ), indicating that the incidence of dyspnea in the severe group was 3.53 times higher than that of non-severe group. On symptoms of diarrhea, we included 266 cases in the severe group (25 cases with diarrhea, 9.40%) and 1,110 cases in the non-severe group (48 cases with diarrhea, 4.32%). Model test showed homogeneity among these studies ( $\text{Chi}^2 = 0.32$ ,  $P = 0.85$ ,  $I^2 = 0\%$ ), and therefore the fixed effect model was used. The combined OR value was 1.80 (95%CI, 1.06-3.03; **Fig. 2C** ), indicating the incidence of diarrhea in the severe group was 1.80 times higher than that of non-severe group. Importantly, the funnel plots of fever, dyspnea and diarrhea are all largely symmetrical, suggesting no significant publication deviation exists (**Fig. 3** ).

### Validation results

The basic characteristics of included patients at admission are shown in **Table 3** . A total of 148 patients were included in this study. Severe cases accounted for 19.6%. The most common symptoms at admission

were fever (81.76%) and cough (61.49%). The less common symptoms were muscle pain (20.27%), fatigue (17.57%) and sore throat (17.57%). The respiratory rate was accelerated on admission in severe patients compared with that in non-severe patients. The proportion of fever in the severe group (96.55%) was higher than that in the non-severe group (78.15%) ( $p=0.021$ ), but the incidence of gastrointestinal symptoms such as diarrhea and abdominal pain was lower.

## Discussion

To our knowledge, this is among the systematic review and meta-analysis of China-based studies comparing the clinical symptoms between patients with severe vs. non-severe form of COVID-19 pneumonia. We observed no gender difference, which is consistent with the latest report<sup>11,13,16,17</sup>. Although fever and cough are relatively common symptoms, we found the incidences of fever, dyspnea and diarrhea are all significantly higher in patients with severe COVID-19 pneumonia, suggesting they could be alarming symptoms that worth extra medical attention. Although our findings in dyspnea were similar to previous reports<sup>10,11</sup>, we have to point out that certain discrepancy exists: for example, some reported no difference in the incidence of fever and diarrhea<sup>10,11,13</sup>, or even dyspnea<sup>13</sup>. One possible explanation is that in those reports, the sample size was relatively small and studies were reported at relatively early phase of this pandemic COVID-19 pneumonia.

The early symptoms/signs of COVID-19 pneumonia can be indistinguishable from those of other common respiratory infectious diseases, and could exhibit certain similarities to those of severe acute respiratory syndrome associated coronavirus (SARS-CoV) and middle East respiratory syndrome coronavirus (MERS-CoV) infections<sup>29,30</sup>. However, patients with COVID-19 rarely had obvious signs and symptoms of upper respiratory tract (e.g. nasal obstruction, rhinorrhea, runny nose, sore throat). In addition, intestinal signs and symptoms such as diarrhea were less common in COVID-19 pneumonia patients (below 10% even in severe form), while about 20-25% of patients with MERS-CoV or SARS-CoV infection presented with diarrhea<sup>30</sup>. It should be noted however that fever in COVID-19 pneumonia patients (10.8%) was more common than SARS-CoV (1%) and MERS-CoV (2%)<sup>31</sup>.

As COVID-19 pneumonia can have a full spectrum of clinical presentations, it is therefore crucially important to recognize alarming symptoms that signal progression to severe form<sup>14</sup>, as such information will not only help us better triage our patients, but also wisely use our medical resources which are often in shortage during pandemic crisis. This study has clearly shown that fever, dyspnea and diarrhea could be such alarming symptoms that warrant timely medical attention. Meanwhile, as can be seen from our validation results, fever and dyspnea are more common in patients with severe COVID-19 pneumonia. However, there was no statistically significant difference between the two groups in gastrointestinal symptoms such as nausea, diarrhea or abdominal pain ( $p > 0.05$ ). However certain limitation exists in this study: 1) since most data are from retrospective studies and case reports, which intend to report successful management, selection bias could exist. However, considering some studies reported that most patients were still hospitalized at the time of publication (for example, 93.6% (1029/1099) in *Article 1* and 61.6% (85/138) in *Article 2*, **Fig. 2**), the selection bias could have little impact; 2) the data collection in some cases is not complete, especially for rare symptoms such as hemoptysis and conjunctivitis, hence the statistical power should be carefully interpreted for those symptoms; 3) from data analysis perspective using published studies, although symmetry was observed, it is challenging to evaluate publication bias due to limited number of studies included. However, since COVID-19 is new disease entity, both positive and negative results will likely have the chance to be published, which should theoretically reduce the publication bias for future secondary analysis.

## Conclusion

Fever, dyspnea and diarrhea were significantly more common in patients with severe COVID-19 pneumonia, suggesting they are alarming symptoms that warrant urgent medical attention.

## Abbreviations

NCP: novel coronavirus pneumonia; ARDS: acute respiratory distress syndrome; SARS-CoV-2: severe acute

respiratory syndrome coronavirus 2; WHO: World Health Organization; NOS: Newcastle-Ottawa quality assessment scale; IQR: interquartile range; OR: odds ratio; SARS-CoV: severe acute respiratory syndrome associated coronavirus; MERS-CoV: middle East respiratory syndrome coronavirus

## Reference

1. WHO. Novel coronavirus – China. <https://www.who.int/csr/don/12-january-2020-novel-coronavirus-china/en/>; 2020 [accessed 19 Jan 2020].
2. Lu R, Zhao X, Li J, Niu P, Yang B, Wu H, et al. Genomic characterisation and epidemiology of 2019 novel coronavirus: implications for virus origins and receptor binding. *Lancet*. 2020;395:565-74.
3. Zhu N, Zhang D, Wang W, Li X, Yang B, Song J, et al. A Novel Coronavirus from Patients with Pneumonia in China, 2019. *N Engl J Med*. 2020;382:727-33.
4. Lu H, Stratton CW, Tang YW. Outbreak of pneumonia of unknown etiology in Wuhan, China: The mystery and the miracle. *J Med Virol*. 2020;92:401-2.
5. Bogoch, II, Watts A, Thomas-Bachli A, Huber C, Kraemer MUG, Khan K. Potential for global spread of a novel coronavirus from China. *J Travel Med*. 2020;27.
6. Li Q, Guan X, Wu P, Wang X, Zhou L, Tong Y, et al. Early Transmission Dynamics in Wuhan, China, of Novel Coronavirus-Infected Pneumonia. *N Engl J Med*. 2020;382:1199-207.
7. Chan JF, Yuan S, Kok KH, To KK, Chu H, Yang J, et al. A familial cluster of pneumonia associated with the 2019 novel coronavirus indicating person-to-person transmission: a study of a family cluster. *Lancet*. 2020;395:514-23.
8. Chen N, Zhou M, Dong X, Qu J, Gong F, Han Y, et al. Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: a descriptive study. *Lancet*. 2020;395:507-13.
9. Huang C, Wang Y, Li X, Ren L, Zhao J, Hu Y, et al. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. *Lancet*. 2020;395:497-506.
10. Guan WJ, Ni ZY, Hu Y, Liang WH, Ou CQ, He JX, et al. Clinical Characteristics of Coronavirus Disease 2019 in China. *N Engl J Med*. 2020.
11. Wang D, Hu B, Hu C, Zhu F, Liu X, Zhang J, et al. Clinical Characteristics of 138 Hospitalized Patients With 2019 Novel Coronavirus-Infected Pneumonia in Wuhan, China. *JAMA*. 2020.
12. Stang A. Critical evaluation of the Newcastle-Ottawa scale for the assessment of the quality of nonrandomized studies in meta-analyses. *Eur J Epidemiol*. 2010;25:603-5.
13. Zhang JJ, Dong X, Cao YY, Yuan YD, Yang YB, Yan YQ, et al. Clinical characteristics of 140 patients infected with SARS-CoV-2 in Wuhan, China. *Allergy*. 2020.
14. WHO. Clinical management of severe acute respiratory infection when novel coronavirus (nCoV) infection is suspected. Interim guidance. Jan 28, 2020.
15. Zhou B. Predictive values of body mass index and waist circumference to risk factors of related diseases in Chinese adult population. *Chin J Epidemiol*. 2002;23:5-10.
16. Yang X, Yu Y, Xu J, Shu H, Xia J, Liu H, et al. Clinical course and outcomes of critically ill patients with SARS-CoV-2 pneumonia in Wuhan, China: a single-centered, retrospective, observational study. *Lancet Respir Med*. 2020.
17. Liu Y, Sun W, Li J, Chen L, Wang Y, Zhang L, et al. Clinical features and progression of acute respiratory distress syndrome in coronavirus disease 2019. *medRxiv*. 2020:2020.02.17.20024166.
18. Chang D, Lin M, Wei L, Xie L, Zhu G, Dela Cruz CS, et al. Epidemiologic and Clinical Characteristics of Novel Coronavirus Infections Involving 13 Patients Outside Wuhan, China. *JAMA*. 2020;323:1092-3.

19. COVID-19, Australia: Epidemiology Report 3 (Reporting week ending 19:00 AEDT 15 February 2020). *Commun Dis Intell* (2018). 2020;44.
20. Wei M, Yuan J, Liu Y, Fu T, Yu X, Zhang ZJ. Novel Coronavirus Infection in Hospitalized Infants Under 1 Year of Age in China. *JAMA*. 2020.
21. Bastola A, Sah R, Rodriguez-Morales AJ, Lal BK, Jha R, Ojha HC, et al. The first 2019 novel coronavirus case in Nepal. *Lancet Infect Dis*. 2020;20:279-80.
22. Bernard Stoecklin S, Rolland P, Silue Y, Mailles A, Campese C, Simondon A, et al. First cases of coronavirus disease 2019 (COVID-19) in France: surveillance, investigations and control measures, January 2020. *Euro Surveill*. 2020;25.
23. Pongpirul WA, Pongpirul K, Ratnarathon AC, Prasithsirikul W. Journey of a Thai Taxi Driver and Novel Coronavirus. *N Engl J Med*. 2020;382:1067-8.
24. Kim JY, Choe PG, Oh Y, Oh KJ, Kim J, Park SJ, et al. The First Case of 2019 Novel Coronavirus Pneumonia Imported into Korea from Wuhan, China: Implication for Infection Prevention and Control Measures. *J Korean Med Sci*. 2020;35:e61.
25. Silverstein WK, Stroud L, Cleghorn GE, Leis JA. First imported case of 2019 novel coronavirus in Canada, presenting as mild pneumonia. *Lancet*. 2020;395:734.
26. Holshue ML, DeBolt C, Lindquist S, Lofy KH, Wiesman J, Bruce H, et al. First Case of 2019 Novel Coronavirus in the United States. *N Engl J Med*. 2020;382:929-36.
27. Liu YC, Liao CH, Chang CF, Chou CC, Lin YR. A Locally Transmitted Case of SARS-CoV-2 Infection in Taiwan. *N Engl J Med*. 2020;382:1070-2.
28. Phan LT, Nguyen TV, Luong QC, Nguyen TV, Nguyen HT, Le HQ, et al. Importation and Human-to-Human Transmission of a Novel Coronavirus in Vietnam. *N Engl J Med*. 2020;382:872-4.
29. Lee N, Hui D, Wu A, Chan P, Cameron P, Joynt GM, et al. A major outbreak of severe acute respiratory syndrome in Hong Kong. *N Engl J Med*. 2003;348:1986-94.
30. Assiri A, Al-Tawfiq JA, Al-Rabeeh AA, Al-Rabiah FA, Al-Hajjar S, Al-Barrak A, et al. Epidemiological, demographic, and clinical characteristics of 47 cases of Middle East respiratory syndrome coronavirus disease from Saudi Arabia: a descriptive study. *Lancet Infect Dis*. 2013;13:752-61.
31. Leung WK, To KF, Chan PK, Chan HL, Wu AK, Lee N, et al. Enteric involvement of severe acute respiratory syndrome-associated coronavirus infection. *Gastroenterology*. 2003;125:1011-7.

#### Figure/Table legend :

**Fig. 1.** The flowchart of selecting studies for this analysis. Careful screening and stringent criteria were used.

**Fig. 2.** The forests plots of fever (A), dyspnea (B) and diarrhea (C). In all cases, these symptoms were found significantly enriched in patients with severe COVID-19 pneumonia.

**Fig. 3.** The funnel plot of fever, dyspnea and diarrhea. They are all largely symmetrical, suggesting no significant publication deviation exists.

**Table 1** A summary of clinical presentations from COVID-19 pneumonia. This is a summary based on 14 eligible studies.

**Table 2** The comparison of clinical features from severe vs. non-severe COVID-19 pneumonia. Here three high-quality studies with used for comparison and statistical analysis.

**Table 3** Basic characteristics at time of hospital admission for COVID-19 patients in Wenzhou, China.

### Hosted file

Table 1.doc available at <https://authorea.com/users/356102/articles/479092-alarming-symptoms-leading-to-severe-covid-19-pneumonia-a-meta-analysis-and-validation>

### Hosted file

Table 2.doc available at <https://authorea.com/users/356102/articles/479092-alarming-symptoms-leading-to-severe-covid-19-pneumonia-a-meta-analysis-and-validation>

### Hosted file

Table 3.docx available at <https://authorea.com/users/356102/articles/479092-alarming-symptoms-leading-to-severe-covid-19-pneumonia-a-meta-analysis-and-validation>



